Cencora is moving ahead with its global 3PL expansion in Europe and the U.S., adding capacity to a logistics network that now has to keep pace with the growing volume of specialty pharmaceuticals. The company is adding new capacity, automation and cold chain infrastructure in key markets, aiming to give manufacturers broader access to third-party logistics services as more complex therapies reach commercial scale.
The expansion advances Cencora’s strategy in Europe, where demand for specialized drug supply management continues to increase. The company is extending its global 3PL expansion through the addition of NextPharma Logistics, which operates across Germany, Austria and Switzerland and provides storage, distribution, serialization and quality compliance through Good Distribution Practice (GDP)-compliant facilities. Cencora also plans to bring a new 3PL site online in Italy in 2026, adding capacity in a part of Europe that has taken on a larger role in the handling of high-value therapies and the tight controls they require.
In the U.S., the company is preparing to add a 500,000-sq.-ft., highly automated facility in Texas in 2028. Once operational, it will be Cencora’s fifth 3PL site in the country. The site will significantly increase storage capacity for controlled, room-temperature, refrigerated, and frozen products, including ultra-low and cryogenic ranges. The investment deepens the company’s cold chain infrastructure and supports its global 3PL expansion for manufacturers seeking dependable logistics for temperature-sensitive pharmaceuticals.
“Our customers trust us to serve as an extension of their operations. We continue to strengthen our pharmaceutical logistics capabilities through investments across our 3PL network to deliver enhanced support tailored to their needs,” said Chris Williams, Senior Vice President and President of Alloga Europe & ICS. “Whether it’s a large-scale global program or supporting the launch of an advanced therapy in a new market, we’re able to provide the integrated support our customers need to navigate supply chain complexities, maximize commercial success, and ensure efficient and reliable access to their products.”
Together, these additions position Cencora to manage a broader mix of specialty medicines that require strict oversight, quality controls, and end-to-end visibility. With a larger footprint, expanded cold chain capacity, and automated handling systems, the company is reinforcing its role as a logistics partner for manufacturers navigating increasingly complex supply chains in established and emerging markets.
